IL98444A - Pharmaceuticals containing retancersrin or segansarin for the treatment of addictive drug addiction - Google Patents
Pharmaceuticals containing retancersrin or segansarin for the treatment of addictive drug addictionInfo
- Publication number
- IL98444A IL98444A IL9844491A IL9844491A IL98444A IL 98444 A IL98444 A IL 98444A IL 9844491 A IL9844491 A IL 9844491A IL 9844491 A IL9844491 A IL 9844491A IL 98444 A IL98444 A IL 98444A
- Authority
- IL
- Israel
- Prior art keywords
- habit
- drugs
- forming
- formula
- ritanserin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 229940079593 drug Drugs 0.000 title claims abstract description 53
- 206010012335 Dependence Diseases 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 title description 21
- 229950009626 ritanserin Drugs 0.000 title description 21
- ZGUPMFYFHHSNFK-UHFFFAOYSA-N 3-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC=1N=C2C=CC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 ZGUPMFYFHHSNFK-UHFFFAOYSA-N 0.000 title description 3
- 229950010947 seganserin Drugs 0.000 title description 3
- 208000024891 symptom Diseases 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 229960003920 cocaine Drugs 0.000 claims description 16
- 229960002428 fentanyl Drugs 0.000 claims description 12
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 239000000380 hallucinogen Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical group C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53717590A | 1990-06-13 | 1990-06-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL98444A0 IL98444A0 (en) | 1992-07-15 |
| IL98444A true IL98444A (en) | 1995-06-29 |
Family
ID=24141527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9844491A IL98444A (en) | 1990-06-13 | 1991-06-11 | Pharmaceuticals containing retancersrin or segansarin for the treatment of addictive drug addiction |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0461705B1 (cs) |
| JP (1) | JPH04230218A (cs) |
| KR (1) | KR920000321A (cs) |
| AT (1) | ATE190488T1 (cs) |
| AU (1) | AU637502B2 (cs) |
| CA (1) | CA2044423A1 (cs) |
| CZ (1) | CZ279872B6 (cs) |
| DE (1) | DE69132036T2 (cs) |
| HU (1) | HU208080B (cs) |
| IE (1) | IE911996A1 (cs) |
| IL (1) | IL98444A (cs) |
| PT (1) | PT97961B (cs) |
| SK (1) | SK278577B6 (cs) |
| ZA (1) | ZA914501B (cs) |
-
1991
- 1991-06-05 DE DE69132036T patent/DE69132036T2/de not_active Expired - Fee Related
- 1991-06-05 EP EP91201383A patent/EP0461705B1/en not_active Expired - Lifetime
- 1991-06-05 AT AT91201383T patent/ATE190488T1/de not_active IP Right Cessation
- 1991-06-11 KR KR1019910009575A patent/KR920000321A/ko not_active Withdrawn
- 1991-06-11 JP JP3165147A patent/JPH04230218A/ja active Pending
- 1991-06-11 AU AU78321/91A patent/AU637502B2/en not_active Ceased
- 1991-06-11 SK SK1780-91A patent/SK278577B6/sk unknown
- 1991-06-11 IL IL9844491A patent/IL98444A/en not_active IP Right Cessation
- 1991-06-11 CZ CS911780A patent/CZ279872B6/cs unknown
- 1991-06-12 CA CA002044423A patent/CA2044423A1/en not_active Abandoned
- 1991-06-12 PT PT97961A patent/PT97961B/pt not_active IP Right Cessation
- 1991-06-12 ZA ZA914501A patent/ZA914501B/xx unknown
- 1991-06-12 IE IE199691A patent/IE911996A1/en unknown
- 1991-06-13 HU HU911971A patent/HU208080B/hu not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69132036T2 (de) | 2000-12-21 |
| DE69132036D1 (de) | 2000-04-20 |
| EP0461705A3 (en) | 1992-06-17 |
| AU637502B2 (en) | 1993-05-27 |
| CS178091A3 (en) | 1992-02-19 |
| CZ279872B6 (cs) | 1995-07-12 |
| EP0461705A2 (en) | 1991-12-18 |
| HU911971D0 (en) | 1991-12-30 |
| KR920000321A (ko) | 1992-01-29 |
| EP0461705B1 (en) | 2000-03-15 |
| SK278577B6 (en) | 1997-10-08 |
| ZA914501B (en) | 1993-02-24 |
| JPH04230218A (ja) | 1992-08-19 |
| AU7832191A (en) | 1991-12-19 |
| IL98444A0 (en) | 1992-07-15 |
| PT97961A (pt) | 1992-03-31 |
| PT97961B (pt) | 1998-11-30 |
| IE911996A1 (en) | 1991-12-18 |
| CA2044423A1 (en) | 1991-12-14 |
| HU208080B (en) | 1993-08-30 |
| ATE190488T1 (de) | 2000-04-15 |
| HUT60628A (en) | 1992-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3221611B2 (ja) | 物質乱用障害の治療用医薬組成物 | |
| IE83379B1 (en) | New use of diphenylbutylpiperazinecarboxamides in the treatment of substance abuse | |
| US5565455A (en) | Method for treating substance abuse disorders | |
| JP3601898B2 (ja) | 薬物依存形成抑制剤 | |
| US5397782A (en) | Method of treating addiction to alcohol | |
| IL98444A (en) | Pharmaceuticals containing retancersrin or segansarin for the treatment of addictive drug addiction | |
| RU2197245C2 (ru) | Пиридил- и пиримидил-пиперазины в лечении болезней, вызываемых злоупотреблением лекарственными и/или наркотическими веществами | |
| NZ260896A (en) | Use of 2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl substituted thiazolopyrimidinone and -pyridopyrimidinone derivatives for preparing medicaments for treating addiction | |
| RU2258506C2 (ru) | Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний | |
| EP0415612A2 (en) | Use of sertraline for the treatment of chemical dependencies | |
| JPWO2001098300A1 (ja) | 神経変性疾患予防・治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |